Brief: Therapeutic Solutions International Files For Orphan Drug Designation Use Of Jadicell Adult Stem Cells
12/07/2023 14:27
July 12 (Reuters) - Therapeutic Solutions International
Inc TSOI.PK :
* THERAPEUTIC SOLUTIONS INTERNATIONAL FILES FOR ORPHAN DRUG
DESIGNATION USE OF JADICELL ADULT STEM CELLS FOR TREATMENT OF
FRONTOTEMPORAL DEMENTIA
Source text for Eikon: ID:nBw4C2B1la
Further company coverage: TSOI.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Therapeutic Solutions International
See all newsBrief: Therapeutic Solutions International Files For Orphan Drug Designation Use Of Jadicell Adult Stem Cells
Brief: Therapeutic Solutions International Files To Initiate Phase Iii Clinical Trial For Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive Covid-19 Data With Jadicell Stem Cell Therapy
Brief: Therapeutic Solutions International Files With FDA To Expand Ongoing Phase III Clinical Trial To Include All Causes Of Acute Respiratory Distress Syndrome
Brief: Therapeutic Solutions Granted Emergency IND By FDA For Stem Cell Therapy
Brief: Therapeutic Solutions International Completes Purchase Of FDA Phase Iii Jadicell Stem Cell Investigational New Drug Application From University Of Miami